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Abstract
Microvillous inclusion disease (MVID) or microvillous atrophy is a congenital disorder of the
intestinal epithelial cells that presents with persistent life-threatening watery diarrhea and is
characterized by morphological enterocyte abnormalities. MVID manifests either in the first days
of life (early-onset form) or in the first two months (late-onset form) of life. MVID is a very rare
disorder of unknown origin, probably transmitted as an autosomal recessive trait. To date, no
prevalence data are available. Ultrastructural analyses reveal: 1) a partial to total atrophy of
microvilli on mature enterocytes with apical accumulation of numerous secretory granules in
immature enterocytes; 2) the highly characteristic inclusion bodies containing rudimentary or fully
differentiated microvilli in mature enterocytes. Light microscopy shows accumulation of PAS-
positive granules at the apical pole of immature enterocytes, together with atrophic band indicating
microvillus atrophy and, in parallel, an intracellular PAS or CD10 positive line (marking the
microvillous inclusion bodies seen on electron microscopy). Intestinal failure secondary to diarrhea
is definitive. To date, no curative therapy exists and children with MVID are totally dependent on
parenteral nutrition. Long-term outcome is generally poor, due to metabolic decompensation,
repeated states of dehydration, infectious and liver complications related to the parenteral
nutrition. As MVID is a very rare disorder, which is extremely difficult to diagnose and manage,
children with MVID should be transferred to specialized pediatric gastro-intestinal centers, if
possible, a center equipped to perform small bowel transplantation. Early small bowel
transplantation resulting in intestinal autonomy gives new hope for disease management and
outcome.




Congenital familial protracted diarrhea with enterocyte
brush-border abnormalities
Definition and diagnostic criteria
Microvillous inclusion disease (MVID) or microvillous
atrophy (MVA) is a congenital and constitutive disorder of
intestinal epithelial cells [1-6]. It is characterized by the
neonatal onset of abundant watery diarrhea persisting
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despite total bowel rest. Onset most often occurs within
the first days of life. Microvillous atrophy, first described
in 1978 [7], was the first clinical entity identified on a
morphological basis as being responsible for the so-called
protracted or intractable diarrhea syndrome. The diagno-
sis is based on typical morphological abnormalities
detected through a combination of light and electron
microscopic (EM) analyses of small bowel biopsies [8-
14]. Standard histology reveals a variable degree of villous
atrophy without marked crypt hyperplasia, in addition to
abnormal periodic-acid schiff (PAS) positive secretory
granules accumulating in the apical cytoplasm of mature
enterocytes and an altered (atrophic after PAS staining)
enterocyte brush border membrane. These findings are
completed by EM with the detection of atrophic or com-
pletely absent microvilli on mature enterocytes (see
below) along with so-called microvillous inclusions (vac-
uoles lined by microvilli) and the finding of large PAS
positive granules in immature enterocytes.
Clinical presentation
Pregnancy and delivery are uneventful; in general, there is
no notion of polyhydramnios except in rare isolated cases.
Severe watery diarrhea starts within the first days of life [1-
4,6,7]. This diarrhea becomes so abundant, that within 24
h the children can loose up to 30% of their body weight,
resulting in profound metabolic acidosis and severe dehy-
dration. MVID is most often severe and life-threatening.
Accurate quantification of the stool volumes reveals 150
to over 300 ml/kg/d, with a high sodium content (approx-
imately 100 mmol/L). Complete and prolonged bowel
rest allows to reduce stool volume moderately, but vol-
umes nearly always remain above 150 ml/kg/day [4].
Inappropriate parenteral nutrition with steadily increas-
ing intravenous fluids may significantly aggravate stool
output. No additional clinical signs are associated with
MVID; in particular, there are no malformations or
involvement of other organs such as liver, kidney etc.
However, a small number of children has a massive pruri-
tus secondary to marked elevations in the concentrations
of biliary acids in the blood. Initially, no specific findings
can be detected except enormous abdominal distension
with fluid-filled intestinal and colonic loops. All children
with congenital MVID urgently require total parental
nutrition (TPN), which often causes rapidly evolving
cholestasis and liver disease. A detailed multicenter anal-
ysis of 23 patients with MVID [4] allowed two different
forms and presentations of MVID to be distinguished on
a clinical and morphological basis: congenital early-onset
MVID (starting within the first days of life), and late-onset
MVID (with first symptoms appearing after two or three
months of life).
Biological testing
Secondary to the marked diarrhea, children with MVID
rapidly develop metabolic acidosis and signs of hypotonic
dehydration. No other biological signs are associated with
this disorder, however, most children are at risk of devel-
oping cholestasis and liver failure. Stool examination
reveals fecal sodium concentrations between 100 and 130
mmol/L, normal alpha-1 antitrypsin clearance, and no
fecal inflammatory parameters.
Endoscopy/Biopsies
The gold standard in the diagnosis of MVID is a combined
light/electron microscopic histological analysis (Figure 1)
of small bowel biopsies obtained during diagnostic gas-
trointestinal endoscopy. Macroscopic endoscopic analysis
of the entire gastro-intestinal tract remains completely
normal, besides non-specific minimal alterations, such as
mild mucosal erythema or, in rare cases, indirect signs of
villous atrophy. In contrast, histological analysis reveals
major alterations of the entire small bowel and, to a lesser
degree, also of the colon. Standard histology shows a var-
iable degree of villous atrophy without marked crypt
hyperplasia, appearing as "thin mucosa" [11,15]. The
accumulation of PAS positive granules within the apical
cytoplasm of immature enterocytes in the upper crypt is
highly characteristic of MVID [13,14]. In parallel, on PAS
staining (light microscopy), the brush border membrane
looks pathological, with an enlarged intracytoplasmic
band along the apical pole of enterocytes (corresponding
to autophagocytic vacuoles and microvillous inclusion
bodies revealed by EM) and an atrophic band instead of
the normally well-defined small line representing the
brush border (Figure 1).
New immuno-staining techniques directed against CD10,
a neutral membrane-associated peptidase, can further
help the diagnosis of MVID [9,14], since the small linear
band of the brush border appears markedly enlarged and
as a double band in MVID patients. This abnormal stain-
ing pattern (PAS or CD10) on the apical pole of entero-
cytes appears first in upper crypt epithelial cells in
congenital MVID with early onset, whereas late-onset
MVID has abnormal enterocyte structures within the
lower villous part. Based on the morphological presenta-
tion of abnormal PAS stain in low crypt cells, an atypical
form of MVID was also described. On EM, mature entero-
cytes show a reduced to completely absent microvillus
profile on the apical membrane, and increased numbers
of autophagic granules [8]. In addition, the diagnostic and
characteristic microvillus inclusion bodies are easily dis-
tinguishable by EM. In contrast to mature enterocytes,
crypt cells appear almost normal on EM apart from
increased number of secretory granules. Thus, the diagno-
sis of MVID is difficult and should be performed or at least
confirmed by particularly skilled pathologists who mostOrphanet Journal of Rare Diseases 2006, 1:22 http://www.OJRD.com/content/1/1/22
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often can make this diagnosis on light microscopy after
PAS or CD10 staining (characteristic alterations in the api-
cal pole of immature and mature enterocytes). However,
the diagnosis is formally confirmed by the finding of
microvillous inclusion bodies within the cytoplasm along
with atrophic microvilli on EM. Since microvilli on imma-
ture crypt cells are most often normal, isolated EM analy-
sis of these cells should not be performed as it could lead
to a false negative diagnosis. In addition, the isolated find-
ing of rudimentary or absent microvilli on enterocytes is
also not sufficient to diagnose MVID with certitude, as dis-
cussed.
Complications
As a result of the severe diarrhea, acute episodes of dehy-
dration and metabolic decompensation are common
complications of MVID. Hypovolemia often causes tem-
porary ischemia, therefore, neurological and psychologi-
cal symptoms such as developmental retardation can
occur [4]. Impaired renal function is also a frequent com-
plication, together with nephrocalcinosis. TPN is
extremely difficult to adapt and requires vast experience,
especially for the initial stabilization of small babies with
MVID. Major complications of TPN such as cholestasis or
liver failure are normally avoidable, but still very frequent.
Infectious complications of the central catheter resulting
in sepsis are the most frequent cause of death, followed by
liver failure.
Outcome
MVID is a constitutive intestinal epithelial cell disease that
causes an irreversible diarrheal disorder leading to perma-
nent and definitive intestinal failure [4,7,16]. Children
with MVID are dependent on exclusive parenteral nutri-
tion throughout their lives. Oral alimentation and appro-
priate oral caloric intake are impossible. There is no hope
for improvement with age. A large number of patients do
not survive the first three years of life as a result of infec-
tious complications or rapid evolution of liver failure.
Those children with MVID who survive often have mental
and statural retardation, and renal complications. In con-
trast to children with early-onset MVID, the diarrhea is
often less severe in children with the late-onset form of the
disease. With age, children with late-onset MVID can
acquire partial intestinal autonomy, resulting in a reduc-
High power magnification of a duodenal section of a patient with typical microvillous inclusion disease or microvillous atrophy  (MVA) after periodic schiff acid (PAS) staining or anti-CD10 immunohistochemistry Figure 1
High power magnification of a duodenal section of a patient with typical microvillous inclusion disease or microvillous atrophy 
(MVA) after periodic schiff acid (PAS) staining or anti-CD10 immunohistochemistry. As shown on both panels compared to 
normal controls, in MVA an enlarged intracytoplasmic band (arrow) along the apical pole of enterocytes is observed along with 
an atrophic band instead of the normally well-defined small line representing the brush border (asterix).Orphanet Journal of Rare Diseases 2006, 1:22 http://www.OJRD.com/content/1/1/22
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tion of the number of perfusions of parental nutrition to
one or two a week.
Etiology
The precise etiology of MVID is still unknown. A major
defect in membrane trafficking in enterocytes has been
proposed as pathogenetic mechanism of MVID, probably
secondary to an altered structure of the cytoskeleton [17].
However, the observation of morphologically normal
microvilli on immature crypt cells in children with MVID
indicate that the microvillous changes seen in differentiat-
ing and mature cells are of a secondary nature or are a con-
sequence of yet unidentified events within the cell. These
events could include membrane recycling or mechanisms
controlling endo- or exocytosis [18,19]. However, analy-
sis of the membrane targeting of disaccharidases, such as
sucrase-isomaltase, revealed no abnormalities of the
direct or indirect constitutive pathway. Very recent obser-
vations indicate a selective defect in glycoprotein exocyto-
sis in patients with MVID [20]. These findings need
further confirmation. Another hypothesis suggesting a
defect in the autophagocytosis pathway was recently pro-
posed to explain the morphological and functional
abnormalities in MVID [21].
Differential diagnosis
Epithelial dysplasia (tufting enteropathy), inflammatory
bowel disorder, autoimmune enteropathies, chloride or
sodium diarrhea, Na-H-exchange deficiency, glucose-
galactose malabsorption, sucrase-isomaltase deficiency,
rarely intestinal pseudo-obstruction syndrome or motility
disorders.
Epidemiology
MVID is an extremely rare congenital disorder. To date, no
prevalence data are available, however, it can be estimated
that there are no more than a few hundred children with
MVID in Europe. The prevalence is higher in countries
with a high degree of consanguinity, suggesting auto-
somal recessive transmission.
Genetic counseling
The observations that the incidence of MVID is higher in
families with a pre-existing case of MVID and that there is
a high rate of consanguinity in parents of children with
MVID, clearly indicate a genetic basis for this disorder,
which is probably inherited on an autosomal recessive
basis. It is particularly striking to note the large number of
children of Turkish origin with MVID and a high degree of
consanguinity in this population. As genetic defect has
not been identified, no genetic counseling or prenatal
diagnosis is possible.
Management including treatment
To date, no causal treatment exists for MVID. Trials with
anti-inflammatory drugs including steroids and anti-
secretory medications (such as sandostatin or lopera-
mide), did not significantly change stool volumes over a
prolonged period [4]. Therefore, all patients are depend-
ent on supportive measures such as parenteral nutrition,
which is the only way of stabilizing them. However, this
treatment is often difficult to administer successfully as
the diarrhea is very abundant and the patients can rapidly
succumb to metabolic decompensation. Therefore, it is
important that children with MVID are transferred to
highly specialized pediatric gastroenterology centers. As
discussed, the long-term outcome is rather poor for chil-
dren treated with parenteral nutrition. New treatment
strategies for the management of MVID are needed. Intes-
tinal transplantation is a clear alternative to parenteral
nutrition for children with MVID [16,22-24]. It can be
performed as isolated small bowel or combined liver-
small bowel transplantation, if significant liver disease
exists. A recent study revealed that the outcome for chil-
dren who had undergone small bowel transplantation for
MVID was much better than that for children undergoing
small bowel transplantation for other indications [16].
Based on this observation and the fact that prolonged
parenteral nutrition has a rather poor outcome, it is now
appropriate to consider early small bowel transplantation
as a first choice treatment of early-onset MVID, allowing
the patients to obtain full intestinal autonomy. However,
it is hoped that a curative treatment will be available in the
near future.
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